, listed on NSE, reported Q3 FY25 revenue of ₹3,821 crore, with net profit at ₹81 crore. Recent launches include GLP-1 peptide Liraglutide in the UK. Biocon Biologics secured US FDA approvals for key biosimilars, enhancing its global presence. However, stock volatility persists due to sector challenges. Technically it has given a breakout.